WO2026067706 - KEAP1 MODULATOR
National phase entry is expected:
Publication Number
WO/2026/067706
Publication Date
02.04.2026
International Application No.
PCT/CN2025/124867
International Filing Date
28.09.2025
Title **
[English]
KEAP1 MODULATOR
[French]
MODULATEUR DE KEAP1
[Chinese]
KEAP1调节剂
Applicants **
HANGZHOU BANGSHUN PHARMACEUTICAL CO., LTD.
Inventors
YANG, Xin
WEN, Qiaodong
JIANG, Shanling
ZHENG, Mei
YIN, Jianming
LV, Yubin
Priority Data
202411379847.5
30.09.2024
CN
202411901465.4
23.12.2024
CN
202510498325.5
21.04.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2552 | |
| EPO | Filing, Examination, Granting | 17097 | |
| Japan | Filing, Examination, Granting | 2438 | |
| South Korea | Filing, Examination, Granting | 2756 | |
| USA | Filing, Examination, Granting | 5140 |
Total:
29,983
Contact Us
Abstract[English]
Disclosed in the present invention are a KEAP1 modulator represented by general formula (I), or a modulator that modulates NRF2 activity by means of modulating KEAP1 activity, a pharmaceutical composition thereof, a preparation method therefor, and the use thereof in the preparation of a drug for prevention and/or treatment of indications related to KEAP1 and NRF2, in particular the treatment of cancers.[French]
La présente invention concerne un modulateur de KEAP1 représenté par la formule générale (I), ou un modulateur qui module l'activité de NRF2 par modulation de l'activité de KEAP1, une composition pharmaceutique de celui-ci, son procédé de préparation et son utilisation dans la préparation d'un médicament pour la prévention et/ou le traitement d'indications liées à KEAP1 et NRF2, en particulier le traitement de cancers.[Chinese]
本发明公开了一种通式(I)所示的KEAP1调节剂，或通过调节KEAP1活性从而调节NRF2活性的调节剂，其药物组合物、制备方法及其在制备、预防和/或治疗与KEAP1和NRF2相关适应症的药物的用途，特别是癌症的治疗。